Blog
RSS FeedPosted by Michael Wonder on 26 Jul 2019
Intellectual property law amends will add to business uncertainty
26 July 2019 - Medicines Australia supports efforts to strengthen Australia’s Intellectual Property arrangements to be consistent with international best ...
Posted by Michael Wonder on 16 Jul 2019
How pharma, under attack from all sides, keeps winning in Washington
16 July 2019 - It does not seem to matter how angrily President Trump tweets, how pointedly House Speaker Nancy ...
Posted by Michael Wonder on 19 Jun 2019
With eyes on Gilead, law makers want details on how HHS reviews possible patent infringement
18 June 2019 - A pair of law makers has asked the Government Accountability Office to review how the U.S. ...
Posted by Michael Wonder on 08 May 2019
They were supposed to talk about the patent system driving up drug prices. But most lawmakers got distracted by small tweaks.
7 May 2019 - If there was any hope that Congress might overhaul the way this country doles out the ...
Posted by Michael Wonder on 02 May 2019
Pharmaceutical protections in U.S. trade deals — what do Americans get in return?
1 May 2019 - U.S. trade deals increasingly include terms affecting the approval process and availability of medicines. ...
Posted by Michael Wonder on 23 Mar 2019
Drug company protections are latest stumbling block for NAFTA rewrite
21 March 2019 - President Trump’s ability to get his revised North American Free Trade Agreement through Congress may hinge ...
Posted by Michael Wonder on 11 Feb 2019
‘One-and-done’ for new drugs could cut patent thickets and boost generic competition
11 February 2019 - In a perfect world, the system for conveying medications from their makers to patients should be ...
Posted by Michael Wonder on 08 Dec 2018
Patent abuse is driving up drug prices. Just look at Lantus.
7 December 2018 - A rare point of consensus following the midterm elections is that Americans are adamant about lowering ...
Posted by Michael Wonder on 01 Dec 2018
AbbVie announces Humira (adalimumab) global patent license with Pfizer
30 November 2018 - AbbVie announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. ...
Posted by Michael Wonder on 07 Nov 2018
AbbVie announces Humira (adalimumab) global patent license with Momenta
6 November 2018 - AbbVie announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product. ...
Posted by Michael Wonder on 19 Oct 2018
Competition watchdog’s appeal over Pfizer ruling dismissed
19 October 2018 - The High Court has dismissed the ACCC’s application to appeal a decision on whether Pfizer’s local ...
Posted by Michael Wonder on 19 Oct 2018
AbbVie announces global resolution of Humira (adalimumab) patent disputes with Fresenius Kabi
18 October 2018 - Agreements provide non-exclusive license to Fresenius Kabi for Humira related intellectual property in the U.S. effective 30 ...
Posted by Michael Wonder on 16 Oct 2018
Drug price transparency won’t end the patent games
17 October 2018 - Just look at Humira, which is keeping its U.S. monopoly as generics hit the European market. ...
Posted by Michael Wonder on 11 Oct 2018
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
11 October 2018 - Resolution paves way for 2018 launch in key European markets and secures US market entry planned in ...
Posted by Michael Wonder on 01 Oct 2018
Age-related macular degeneration: treatment at what cost?
29 September 2018 - An estimated 8·4 million people worldwide have moderate to severe vision loss caused by age-related macular degeneration. ...